ClinicalTrials.gg
RecruitingNCT03830801IVLCMUpdated Nov 10, 2026

Pilot Study for OCT Guided In Vivo Laser Capture Microdissection for Assessing the Prognosis of Barrett's Esophagus

An interventional study of IVLCM tethered capsule in Barrett Esophagus, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Dec 2017, registered Jan 2019).
  • Started Dec 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Barrett Esophagus by Massachusetts General Hospital — 3 open to participants now, 6 under way, none of them phase 3. Barrett Esophagus · Massachusetts General Hospital.

Planned enrollment
8th of 13
30 · median 50
Started
2017
with 1 other
No phase
13 of 17
3 open now
Registered
16th of 17
by date

Among the 17 studies in Barrett Esophagus by Massachusetts General Hospital, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2017, is one of 13 with no phase, and was the 16th registered.

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

Browse Barrett Esophagus studies →

Open to participants now

3 of the 17 studies in Barrett Esophagus by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Barrett Esophagus by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The investigators have developed a new technology, termed in-vivo laser capture microdissection (IVLCM), that addresses the limitations of endoscopic biopsy for screening for BE and provides targeted genomic profiling of aberrant tissue for more precise prediction of EAC risk. The device is a tethered capsule endomicroscope (TCE) that implements optical coherence tomography (OCT) to grab 10-mm-resolution, cross-sectional microscopic images of the entire esophagus after the capsule is swallowed. This OCT-based TCE technology is used in unsedated patients to visualize images of BE and dysplastic BE. During the IVLCM procedure, TCE images of abnormal BE tissue are identified in real time and selectively adhered onto the device. When the capsule is removed from the patient, these tissues, targeted based on their abnormal OCT morphology, are sent for genomic analysis. By enabling the precise isolation of aberrant esophageal tissues using a swallowable capsule, this technology has the potential to solve the major problems that currently prohibit adequate BE screening and prevention of Esophageal Adenocarcinoma EAC.

Read the detailed description

In Vivo Laser Capture Microdissection (IVLCM). The IVLCM tethered capsule is identical to those used in current approved OCT TCE studies.The capsule is swallowed by the patient and then, in real time, a region for tissue capture, is identified on the images. When a targeted site is identified, a capture laser (1450 nm, 0.8 W, 1 second exposure; within the range of the previously approved OCT-TCE tissue marking study) irradiates this area in the patient, heating the water in the tissue and transforming it to steam. The accumulated water steam overcomes the tissue matrix's adhesion force, ejecting a small amount of tissue and integrating it with the capsule's external shell. This process may then be repeated to collect multiple samples. After the device is pulled out from the patient, the captured tissues can be extracted for genomic analysis. Ex vivo animal tissue studies have shown that capture laser does not damage DNA/RNA; high quality whole genome information can be obtained.

In this IVLCM study, the investigators are using a 1450 nm laser to capture tissue that was previously approved to make cautery "marks" in the esophagus. The IVLCM capture laser's specifications are the same as those of the marking laser and the power will be within the IRB approved power range (0.82 W 1s). Prior to testing laser marking in humans, the investigators first demonstrated the safety of laser marking in animals in vivo. Histological assessment showed that the cautery marks did not penetrate through the submucosa and the vast majority of the effects were limited to the epithelium, lamina propria, and muscularis mucosa layers. The extent of thermal damage was comparable to conventional biopsies in standard of care endoscopic biopsy procedures. After this animal study, the investigators conducted a pilot study in humans in which over 30 marks were made in 22 enrolled subjects without any adverse events or safety concerns. In addition to these balloon studies, the investigators are currently conducting a TCE marking study. So far, the investigators have imaged and marked 13 subjects through a capsule without any adverse effects or safety concerns.

Thirty (N=30) subjects will be enrolled in this study.

03

Conditions studied

  • Barrett Esophagus

Browse trials for

Keywords

  • Barrett's Esophagus
  • EGD
  • Endoscopy
  • Biopsy
  • Tethered Capsule Endomicroscopy
  • OCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a current or prior diagnosis of Barrett's Esophagus
  • Participants must be over the age of 18.
  • Participants must be able to give .

Exclusion criteria

Exclusion Criteria:

  • Pregnant women.
  • Participants who are on anti- medications or anti-coagulation medications, and NSAIDS at the time of procedure.
  • Participants with a history of hemostasis disorders.
  • Participants with esophageal strictures, resulting in a luminal diameter smaller than the diameter of the capsule.
  • Participants with a know history of esophageal varices
  • Participants above 80 years of age
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    IVLCM tethered capsule for biopsies

    IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.

    Device: IVLCM tethered capsule

Interventions

  • DeviceIVLCM tethered capsule

    Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule

06

What researchers measure

Primary outcomes

  1. The number of participants from which we will be able to collect biopsy samples using IVLCM technique

    We will measure the number of subjects from which we will be able to collect biopsy samples using IVLCM technique

    Time frame: 5 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Dec 2027, 120 months after the start.

Of 65 non-industry interventional studies with no phase under Barrett Esophagus, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 108. This study's planned 120 months is above that.

Counting every sponsor, half of 76 studies reached it within 45 months; a quarter within 23 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2019
First posted
Feb 5, 2019
StartActual
Dec 6, 2017
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03830801
Responsible party
Guillermo Tearney (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Feb 5, 2019
Start date
Dec 6, 2017
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Anita Chung, RN
Contact
Tearneylabtrials@partners.org
617-724-4515
Camila Salcedo, CRC
Contact
Tearneylabtrials@partners.org
617-724-4515
Gary Tearney, MD., PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion